Clinical trials: Response Evaluation
Adult Onset Rheumatoid Arthritis
A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).
- Trial name
- NCT02780388
- Testing
- VIB4920
- Where
- 12 sites in United States, Poland
- Volunteers
- 57 people
- Sponsor
- Amgen
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Gastroenteritis
A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants
The purpose of this study is to evaluate the immune response and safety of the inactivated poliovirus (IPV) vaccine when co-administered with the human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in healthy Chinese…
- Trial name
- NCT06331156
- Testing
- HRV PCV-free, IPV
- Where
- 5 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects
This study will enroll 25 patients with kidney disease to evaluate the effects of different doses of sodium bicarbonate (baking soda) on levels of bicarbonate in the blood, kidney function and muscle strength.
- Trial name
- NCT00888290
- Testing
- Sodium bicarbonate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Albert Einstein College of Medicine
Pain, Hyperalgesia
Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia
The aim of this study was to determine if the addition of ketamine reduces remifentanil-induced hyperalgesia, improves its analgesic effect, inhibits IL(interleukin)-6 and IL-8 (inflammatory cytokines), and stimulates IL-10 (an…
- Conditions
- Pain, Hyperalgesia, Inflammatory Response
- Trial name
- NCT01301079
- Testing
- Ketamine, Saline
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Federal University of São Paulo
Smoking
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing…
- Trial name
- NCT02396381
- Testing
- THS 2.2, CC
- Where
- 19 sites in United States
- Volunteers
- 1,039 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Triple-negative Metastatic Breast Cancer
CISPLATIN + AZD-1775 In Breast Cancer
This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body.
- Trial name
- NCT03012477
- Testing
- Cisplatin, AZD1775
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Dana-Farber Cancer Institute
Anaemia
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in…
- Trial name
- NCT01977482
- Testing
- GSK1278863, rhEPO
- Where
- 107 sites in United States, Australia and 14 more
- Volunteers
- 216 people
- Sponsor
- GlaxoSmithKline
Malaria, Severe Malaria
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Background: Malaria is caused by small parasites carried by some mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells.
- Trial name
- NCT01955382
- Testing
- Actidose Aqua, Artesunate, Amodiaquine
- Where
- Mali
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sepsis
Algorithm for Predicting the Unfavorable Course of Sepsis in Children
A comprehensive strategy will be used to investigate the relationship and correlation between 4 diagnostically significant markers relevant for early diagnosis and prediction of complications and death in the development of…
- Trial name
- NCT05908162
- Testing
- Bood leukocyte subsets
- Where
- Belarus
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- The Republican Research and Practical Center for Epidemiology and Microbiology
HIV-1-infection
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
- Trial name
- NCT03570918
- Testing
- MGD014
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- MacroGenics
Chronic Stable Angina
Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.
- Trial name
- NCT01239511
- Testing
- green tea polyphenols (STA-2)
- Where
- 5 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- Sinphar Pharmaceutical Co., Ltd
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Dry Eye
Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)
The purpose of the study is to analyze the sensation to eye drops containing menthol in people with healthy eyes and in people with dry eyes. This study also examines the temperature of your eye using an Infrared Camera.
- Trial name
- NCT02985827
- Testing
- Rohto (r) Hydra, Systane (r) Ultra
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Healthy
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once…
- Trial name
- NCT03979820
- Testing
- BI 1467335, Phenelzine sulfate, Tyramine
- Where
- Netherlands
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)